

Nepal

Support for Vaccine: Pneumococcal This Decision Letter sets out the Programme Terms of a Programme.

1.	Country:	Nepal						
2.	Vaccine grant number:			14-NPL-08c-Y, 1416-NPL-12b-X, 17-NPL-12b-X, 18-NPL-25a-Y, 1821-NPL-12a-X				
3.	Date of Decision Letter:			30 September 2019				
4.	. Date of the Partnership Framework A		amework Ag	greement: 22 August 2014				
5.	i. Programme title: New		New Vaccine	Support (NVS	S), Pneumoco	ccal , Routine)	
6.	. Vaccine type: Pneumocoo		Pneumococc	al				
7.	7. Requested product presentation and f PCV10, 4 dose(s) per vial, LIQUID			ormulation o	f vaccine:			
8.	2014 Programme Duration:		2014-2021					
9.	9. Programme Budget (indicative): ²			(subject to the terms of the Partnership Framework Agreement, if applicable)				
		2014-2019	2020	2021	2022	2023	2024	Total ²
	Programme Budget (US\$)	35,297,226	4,524,500	5,630,000	-	-	-	45,451,726

10. Vaccine introduction grant

Approval				
Year	Year Grant Number Amount (US\$)			
2014	14-NPL-08c-Y	551,000		

Disbursement				
Disbursement date Amount (US\$)				
26 February, 2014	551,000			

11. Product switch grant

Approval					
	Approval				
Year	Grant Number	Amount (US\$)			
2018	18-NPL-25a-Y	160,636			

Disbursement			
Disbursement date Amount (US\$)			
06 June, 2018	31,158		
29 May, 2018	129,478		

¹ This is the entire duration of the programme. ² This is the total amount endorsed by Gavi for the entire duration of the programme.

³ This is the amount that Gavi has approved.



(subject to the terms of the Partnership Framework Agreement, if 12. Indicative Annual Amounts:3 applicable)

Type of supplies to be purchased with Gavi funds		2020	2021
Number of vaccine doses		1,362,200	-
Annual Amounts (US\$)	35,297,226	4,524,500	-

UNICEF. The Country shall release its co-financing payments each year to 13. Procurement agency:

UNICEF.

14. Self-procurement: Not applicable

15. Co-financing obligations:

According to the co-financing policy, the Country falls within the group:

Initial self-financing

The following table summarises the co-financing payment(s) and quantity of supply that will be procured with such funds in the relevant year.

Type of supplies to be purchased with Country funds in each year	2020	2021	2022	2023	2024
Number of vaccine doses	94,800	127,200	-	-	-
Number of AD syringes	-	-	-	-	-
Number of re-constitution syringes	-	-	-	-	-
Number of safety boxes	-	-	-	-	-
Value of vaccine doses (US\$)	289,011	387,698	-	-	1
Total co-financing payments (US\$) (including freight)	291,500	391,500	-	-	-

16. Operational support for campaigns:

Not applicable

17. Additional Reporting Requirements:

		Due dates
To prepare for the annual procurement of vaccines, Country shall submit the		
following information each year:		
•	vaccine stock levels including buffer stock, by end of March;	31 March 2020
•	number of children to be vaccinated, wastage rates, any proposed changes in product, presentation or use, or minimum co-financing levels and vaccines received, by mid-May.	15 May 2020



 Countries shall report the actual switch date in the first renewal request following the actual implementation. 	
In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.	To be agreed with Gavi Secretariat

18. Financial clarifications:

Country shall provide the following clarifications to Gavi*:

Not applicable

* Failure to provide the financial clarifications requested may result in Gavi withholding further disbursements.

19. Other conditions:

Not applicable

Signed by,

On behalf of Gavi

Thabani Maphosa

Managing Director, Country Programmes

30 September 2019